首页 >
法规速递
-
Document: Start of procedure: Type II variation - Extension of indication under evaluation by the CHMP (25 July - 21 August 2025)-2025/9/8
2025-09-09查看详情 > -
Page: European Shortages Monitoring Platform (ESMP)-2025/10/10
2025-10-11查看详情 > -
国家药监局药审中心关于发布《多联疫苗临床试验技术指导原则》的通告（2025年第48号）-2025/11/18
2025-11-19查看详情 > -
Document: Work plan for the CVMP Novel Therapies & Technologies Working Party (NTWP) 2026-2025/12/12
2025-12-15查看详情 > -
Document: Annex to agenda of the CHMP meeting 26-29 January 2026-2026/1/26
2026-01-27查看详情 > -
Document: Darwin EU study: Clozapine and the incidence of severe neutropenia over time-2026/3/4
2026-03-05查看详情 > -
Page: Scientific Advisory Group on Immune and Inflammatory Diseases-2026/4/1
2026-04-02查看详情 > -
Regulatory and procedural guideline: ICH guideline Q3C (R8) on impurities: guideline for residual solvents - Step 5-2022/11/28
2022-11-30查看详情 > -
Final Guidance: Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals-2023/6/2
2023-06-05查看详情 > -
国家药监局关于适用《Q13：原料药和制剂的连续制造》国际人用药品注册技术协调会指导原则的公告（2023年第158号）-2023/12/14
2023-12-21查看详情 >
